Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Warner Chilcott, a specialty pharmaceutical company, has announced that one of its subsidiaries and Mayne Pharma International have filed a lawsuit against Actavis Elizabeth in the District Court of New Jersey for infringement of Mayne's US patent, which covers Doryx, a tetracycline-class oral antibiotic.
Subscribe to our email newsletter
Warner Chilcott markets and sells Doryx delayed-release tablets in 150, 100 and 75mg strengths under a licensing agreement with Mayne. Warner Chilcott has previously announced the filing of similar lawsuits against each of Mutual Pharmaceutical Company, Mylan Pharmaceuticals, Impax Laboratories and Sandoz.
The lawsuit is in response to the submission of an abbreviated new drug application to the FDA by Actavis requesting approval to manufacture and sell generic versions of Doryx 100 and 75mg delayed-release tablets prior to the expiration in 2022 of the patent. Warner Chilcott and Mayne intend to vigorously defend the patent and pursue their legal rights.